Hematology Emergencies: Problems with Platelets

Size: px
Start display at page:

Download "Hematology Emergencies: Problems with Platelets"

Transcription

1 Hematology Emergencies: Problems with Platelets Christian Cable, MD, FACP Associate Professor of Medicine Division of Hematology & Oncology Texas A&M HSC College of Medicine Scott & White Healthcare Fundamentals of Hospital Medicine Temple, TX 1/11/2013

2 Learning Objectives Recognize three distinct, scary inpatient low platelet problems Utilize relevant pathophysiology to distinguish these entities Enable participants to initiate appropriate diagnostic and therapeutic maneuvers

3 Disclosures I love the blood I am especially fond of platelets I am not a vampire I only take money from Scott & White, American College of Physicians, and my wife

4 The Call...

5

6 What could go wrong?

7 Figure 1. Large ecchymotic area over the thigh following minor trauma Lazarchick, J. ASH Image Bank 2001;2001: Copyright 2001 American Society of Hematology. Copyright restrictions may apply.

8 Platelet Problems Platelets in health Why we bleed ITP TTP HIT Conclusions

9 Platelet Problems Platelets in health Why we bleed ITP TTP HIT Conclusions

10 Figure 1. Granulocytes circulating in the blood of a patient with a normal peripheral smear Maslak, P. ASH Image Bank 2008;2008: Copyright 2008 American Society of Hematology. Copyright restrictions may apply.

11 What is that? dust on the slide Early 1900 s - - inert plug Currently - - inert but poised *metabolically active*

12 Figure 1. The granular appearance of the platelets helps to distinguish them from artifact in the peripheral smear Maslak, P. ASH Image Bank 2005;2005: Copyright 2005 American Society of Hematology. Copyright restrictions may apply.

13 Figure 1. Damage to the vascular endothelium results in recruitment of platelets which aggregate at the site, forming the primary hemostatic plug Maslak, P. ASH Image Bank 2008;2008: Copyright 2008 American Society of Hematology. Copyright restrictions may apply.

14 Figure 2. Through the processes of adhesion, aggregation, and secretion, platelets successfully coalesce to complete the formation of the primary hemostatic plug Maslak, P. ASH Image Bank 2008;2008: Copyright 2008 American Society of Hematology. Copyright restrictions may apply.

15 Figure 1. Secondary hemostasis involves the deposition of fibrin which results in fine clot formation Maslak, P. ASH Image Bank 2008;2008: Copyright 2008 American Society of Hematology. Copyright restrictions may apply.

16 Hoffman Hematology, 5 th ed. Fig 114-7

17 Hoffman Hematology, 5 th ed. Fig 115-1

18 UpToDate, 17.1

19 Hoffman Hematology, 5 th ed. Fig 116-2

20 Nachman, NEJM Sept 18, 2008

21 Platelets...

22 ... plug the holes.

23 Platelet Problems Platelets in health Why we bleed ITP TTP HIT Conclusions

24 Nachman, NEJM Sept 18, 2008

25 Nachman, NEJM Sept 18, 2008

26 How low can you go?

27 Spontaneous Bleeding... <10

28 Platelet Problems Platelets in health Why we bleed ITP TTP HIT Conclusions

29 CC: 39 weeks pregnant, low platelets 26 y.o. woman Modest bruising, close to delivery CBC...

30

31 Figure 2. Peripheral smear in a patient with ITP showing an almost total absence of platelets Lazarchick, J. ASH Image Bank 2001;2001: Copyright 2001 American Society of Hematology. Copyright restrictions may apply.

32 Immune TP F ab F Cγ

33 Bromberg, NEJM Oct 19, 2006

34 When giants roamed the halls...

35 ITP treatment Decrease antibody production Block antibody coated platelets from being destroyed in spleen Increase platelet production Transfusion Stimulate thrombopoeisis

36 ITP treatment Steroids IV immune globulin Splenectomy Platelet transfusions if bleeding New agents to increase platelet production

37

38 Success?

39 Platelet Problems Introduction Platelets in health Why we bleed ITP TTP HIT Conclusions

40 CC: Seizure, low platelets 39 y.o. AA woman with known seizures To ER for recurrent seizures, bruising on exam CBC...

41

42 Figure 1. Peripheral smear showing microangiopathic hemolytic features with numerous RBC fragments (helmet cells/schistocytes) Lazarchick, J. ASH Image Bank 2001;2001: Copyright 2001 American Society of Hematology. Copyright restrictions may apply.

43 Thrombotic TP Microangiopathic hemolytic anemia + thromobocytopenia is a very short list. The list does NOT include ITP. TTP is caused by an antibody directed against a protease that cleaves the vonwillebrand molecule. Longer vwf is more sticky and causes platelets to stick in small vessels. This causes multi-organ ischemia and the shearing of red cells.

44 UpToDate, 17.1

45 Harrison s, 17 th ed. Fig 109-4

46 ADAMTS-13 protease F ab F Cγ

47

48 CONTRAindications to Transfusion Platelets - - if the platelets are on fire, don t add more TTP HIT

49

50 x 48 treatments

51 Success?

52 Platelet Problems Platelets in health Why we bleed ITP TTP HIT Conclusions

53 NEJM 355;8 (809-17) August 24, 2006

54 In the Water?

55 HIT - - working diagnosis A decrease in platelet count (<150K or >50%) associated with heparin exposure in a typical time course that has a high risk of thrombotic (not bleeding) complications which requires alternative anticoagulation upon diagnosis.

56 Heparin in the Hospital Orthopedic Surgery Cardiac Surgery General Medical Patients Acute Coronary Syndrome - - PCI Acute Hemodialysis Kids Pregnancy Chronic Hemodialysis

57 Types of Heparin Unfractionated (15kDa~45 saccharide) LMWH (5kDa ~ 15 saccharide) Super LMWH (1.7 kda pentasaccharide) Interact with AT and Xa to reverse coagulation (Super LMWH just Xa)

58 How Heparin Works WARNING - - clotting cascade Tissue Factor F VII

59 WARNING - - clotting cascade F X F VIIa

60 WARNING - - clotting cascade F Xa Prothrombin

61 WARNING - - clotting cascade Thrombin

62 WARNING - - clotting cascade Thrombin Fibrinogen Fibrin

63 WARNING - - clotting cascade Anti-thrombin Thrombin Fibrinogen Fibrin

64 Heparin WARNING - - clotting cascade Anti-thrombin Thrombin Fibrinogen Fibrin

65 Heparin WARNING - - clotting cascade Anti-thrombin Thrombin Fibrinogen Fibrin

66 Heparin WARNING - - clotting cascade Anti-thrombin Thrombin Fibrinogen Fibrin

67 Heparin Pathophysiology Platelet PF4

68 Heparin Pathophysiology Platelet Y PF4 Y

69 Platelets coated by antibodies Aggregate (like a Coombs test) Cleared by spleen (thrombocytopenia) Activated (thrombosis) Platelet PF4 Y

70 Diagnosis Timing Thrombocytopenia Thrombosis Alternate Causes

71 Timing In a patient exposed to heparin for the first time in 100 days, HIT begins after 4-14 days of heparin use A rapid fall in platelets soon after heparin is unlikely to be HIT

72 Thrombocytopenia <150K 50% fall from peak It is uncommon for HIT to cause single digit thrombocytopenia

73 Thrombosis Even after stopping heparin 50% of patients with HIT will clot within the first 30 days Odds ratio for clot w/ HIT = 37 Venous > Arterial DVT/PE most common Weird clots - - HIT more likely

74 Management 2 Do 2 Don t 2 Tests

75 DO Stop ALL heparin - - even flushes Start alternative anticoagulation - - before confirmatory tests return

76 Alternative Anticoagulation Direct Thrombin Inhibitors Lepirudin Not good in kidney dysfunction Argatroban Really messes up the INR Fondaparinux to temporize?

77 DON T Use coumadin too soon - - wait for full platelet recovery, must have sufficient overlap Transfuse platelets - - along with TTP this is a contraindicated condition for platelet transfusions!

78 2 Tests ELISA for antibody to PF4 (usually a sendout, but the most helpful confirmatory test) Bilateral LE Doppler Venous Ultrasound (the presence of thrombosis greatly strengthens your case)

79 Platelet Problems Introduction Platelets in health Why we bleed ITP TTP Conclusions

80 The Call...

81

82

83

84 Diagnosis? ITP Should not have red cell changes Can give platelets Plasma exchange not helpful HIT Needs the H! No platelets TTP Schistocytes No platelets Needs plasma exchange

85 Success?

86

87 Platelet Problems Platelets in health Why we bleed ITP TTP HIT Conclusions

88

Heparin Induced Thrombocytopenia. Heparin Induced Thrombocytopenia. Heparin Induced Thrombocytopenia. Temporal Aspects.

Heparin Induced Thrombocytopenia. Heparin Induced Thrombocytopenia. Heparin Induced Thrombocytopenia. Temporal Aspects. Heparin Induced Eric Kraut, MD Professor of Internal Medicine The Ohio State University Medical Center Heparin Induced Heparin induced thrombocytopenia occurs in up to 5 % of patients receiving unfractionated

More information

Platelet Factor IV- Heparin Antibodies. Presenter: Michael J. Warhol, M.D.

Platelet Factor IV- Heparin Antibodies. Presenter: Michael J. Warhol, M.D. Platelet Factor IV- Heparin Antibodies Presenter: Michael J. Warhol, M.D. Learning Objectives Describe the mechanism of interaction between Heparin and Platelet Factor 4 Review the chemistry of Heparin

More information

10/8/2013. Drug-induced immune thrombocytopenia (DITP) Clinical aspects

10/8/2013. Drug-induced immune thrombocytopenia (DITP) Clinical aspects Richard Aster, MD Blood Center of Wisconsin, Blood Research Institute, Milwaukee, WI Senior Investigator Medical College of Wisconsin Professor, Departments of Medicine & Pathology Drug-induced immune

More information

Platelet type bleeding: (vwd) - Petechiae, purpura, ecchymoses, bruising - Menorrhagia, hematuria, occult GI bleed - Gingival bleeding, epistaxis

Platelet type bleeding: (vwd) - Petechiae, purpura, ecchymoses, bruising - Menorrhagia, hematuria, occult GI bleed - Gingival bleeding, epistaxis 1 Nadanotes.com 2 Nadanotes.com 3 Nadanotes.com Platelet type bleeding: (vwd) - Petechiae, purpura, ecchymoses, bruising - Menorrhagia, hematuria, occult GI bleed - Gingival bleeding, epistaxis Clotting

More information

Session 1 Topics. Vascular Phase of Hemostasis. Coagulation Pathway. Action of Unfractionated Heparin. Laboratory Monitoring of Anticoagulant Therapy

Session 1 Topics. Vascular Phase of Hemostasis. Coagulation Pathway. Action of Unfractionated Heparin. Laboratory Monitoring of Anticoagulant Therapy ~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 1 of 4 Session 1 Topics Review of coagulation and the vascular phase of hemostasis Unfractionated heparin Low molecular

More information

Lina Al-Lawama. Rama Al-Ashqar. Malik Al-Zohlof

Lina Al-Lawama. Rama Al-Ashqar. Malik Al-Zohlof 2 Lina Al-Lawama Rama Al-Ashqar Malik Al-Zohlof Anticoagulant drugs Recap Last lecture we were talking about antiplatelet drugs, we mentioned 5 drugs : Aspirin which is used alone with patents that have

More information

If not heparin for bypass then what? Dr Tony Moriarty Consultant Cardiac Anaesthetist Birmingham United Kingdom

If not heparin for bypass then what? Dr Tony Moriarty Consultant Cardiac Anaesthetist Birmingham United Kingdom If not heparin for bypass then what? Dr Tony Moriarty Consultant Cardiac Anaesthetist Birmingham United Kingdom Heparin Discovered 1916, commercial available 1935 Heparin Is there an alternative, not really

More information

Coagulation Mechanisms Dr. Nervana Bayoumy

Coagulation Mechanisms Dr. Nervana Bayoumy Coagulation Mechanisms Dr. Nervana Bayoumy Associate Professor Department of Physiology Objectives At the end of this lecture you should be able to: 1. Recognize the different clotting factors 2. Understand

More information

Physician Orders - Adult

Physician Orders - Adult Physician Orders - Adult attach patient label here Title: Direct Thrombin Inhibitor (DTI) Protocol Orders Height: cm Weight: kg Allergies: [ ] No known allergies [ ]Medication allergy(s): [ ] Latex allergy

More information

Introduction Hemostasis: Tourniquet Test & Bleeding Time. Hematology-Immunology System Faculty of Medicine Universitas Padjadjaran LOGO

Introduction Hemostasis: Tourniquet Test & Bleeding Time. Hematology-Immunology System Faculty of Medicine Universitas Padjadjaran LOGO Introduction Hemostasis: Tourniquet Test & Bleeding Time Hematology-Immunology System Faculty of Medicine Universitas Padjadjaran LOGO Hemostasis A series of reactions that function to stop bleeding, maintaining

More information

Hemostasis/Thrombosis IV

Hemostasis/Thrombosis IV Hemostasis/Thrombosis IV Antithrombotic Therapy Antithrombotic Therapy Mainstay of battle against thromboembolic disease Hot area of new drug research Cannot inhibit clot formation without increased risk

More information

Management of Bleeding in the Anticoagulated Patient Short Snappers CSIM 2015 Elizabeth Zed, MD, FRCPC October 17, 2015

Management of Bleeding in the Anticoagulated Patient Short Snappers CSIM 2015 Elizabeth Zed, MD, FRCPC October 17, 2015 + Management of Bleeding in the Anticoagulated Patient Short Snappers CSIM 2015 Elizabeth Zed, MD, FRCPC October 17, 2015 + Disclosures Off label use of PCC and apcc will be discussed My centre participates

More information

LABORATORY APPROACH TO BLEEDING DISORDERS DR NISHANTH PG 1 ST YEAR DEPARTMENT OF PATHOLOGY

LABORATORY APPROACH TO BLEEDING DISORDERS DR NISHANTH PG 1 ST YEAR DEPARTMENT OF PATHOLOGY LABORATORY APPROACH TO BLEEDING DISORDERS DR NISHANTH PG 1 ST YEAR DEPARTMENT OF PATHOLOGY 1 WHEN IS THE LAB REQUIRED TO INVESTIGATE FOR A POSSIBLE BLEEDING DISORDER? Clinically suspected bleeding tendency

More information

New Insights into the Diagnosis & Management of Venous Thromboembolism (VTE) Michael Miller, M.D.

New Insights into the Diagnosis & Management of Venous Thromboembolism (VTE) Michael Miller, M.D. New Insights into the Diagnosis & Management of Venous Thromboembolism (VTE) Michael Miller, M.D. Professor of Cardiovascular Medicine University of Maryland School of Medicine Copyright A.P. Wheeler 2009

More information

Bivalirudin (Angiomax ) vs. Heparin during Peripheral Vascular Interventions: Which is Better and How to Decide?

Bivalirudin (Angiomax ) vs. Heparin during Peripheral Vascular Interventions: Which is Better and How to Decide? Bivalirudin (Angiomax ) vs. Heparin during Peripheral Vascular Interventions: Which is Better and How to Decide? Vinod Nair MD FACC FSCAI Cardiovascular Ins6tute of the South, Houma Financial Disclosure:

More information

General Principles of. Hemostasis. Kristine Krafts, M.D.

General Principles of. Hemostasis. Kristine Krafts, M.D. General Principles of Hemostasis Kristine Krafts, M.D. Hemostasis is a balancing act! pro-ting plugs up holes in blood vessels anti-ting keeps ting under control Pro-Clotting Pro-Clotting vessels platelets

More information

ANTICOAGULANT THERAPY ANTICOAGULANT THERAPY REVISITED Thrombosis is a complication of underaggressive anticoagulant therapy

ANTICOAGULANT THERAPY ANTICOAGULANT THERAPY REVISITED Thrombosis is a complication of underaggressive anticoagulant therapy ANTICOAGULANT THERAPY REVISITED 2004 or, Which one(s) of these (#$%$#!@#^) drugs should be the one(s) I use, and for what? ANTICOAGULANT THERAPY One of most common treatments in hospital & out 2 nd most

More information

Managing the Risks Associated with Anticoagulant Therapy. Steve McGlynn Specialist Principal Pharmacist (Cardiology) NHS Greater Glasgow and Clyde

Managing the Risks Associated with Anticoagulant Therapy. Steve McGlynn Specialist Principal Pharmacist (Cardiology) NHS Greater Glasgow and Clyde Managing the Risks Associated with Anticoagulant Therapy Steve McGlynn Specialist Principal Pharmacist (Cardiology) NHS Greater Glasgow and Clyde Background Identified as high risk medicines Wide range

More information

Heparin Induced Thrombocytopenia

Heparin Induced Thrombocytopenia Screen Heparin Induced Thrombocytopenia This course has been awarded one (1) contact hour. This course expires on September 30, 2018. Copyright 2007 by RN.com. All Rights Reserved. Reproduction and distribution

More information

Antithrombotic Therapies: Parenteral Agents

Antithrombotic Therapies: Parenteral Agents Antithrombotic Therapies: Parenteral Agents Christine A. Sorkness, Pharm.D. Professor of Pharmacy & Medicine (CHS) UW School of Pharmacy Clinical Pharmacist, Anticoagulation Clinic, Wm S. Middleton VA

More information

Coagulation in perspective: Blood management. Objectives

Coagulation in perspective: Blood management. Objectives Coagulation in perspective: Blood management Julie Wegner, PhD jawrbl@gmail.com Objectives To gain a basic understanding of the following: 1. Coagulation components and processes Why patients bleed. 2.

More information

Managing Coagulation Abnormalities Linda Liu, M.D.

Managing Coagulation Abnormalities Linda Liu, M.D. Managing Coagulation Abnormalities Professor UCSF Dept of Anesthesia UC SF 1 Difficult Task Coagulation Abnormalities 30 minutes Emphasis on 2 new oral anticoagulants Dabigatran Rivaroxaban UC SF 2 UC

More information

Heparin-Induced Thrombocytopenia and New Anticoagulants

Heparin-Induced Thrombocytopenia and New Anticoagulants Heparin-Induced Thrombocytopenia and New Anticoagulants September 2004 Elizabeth M. Van Cott, MD Massachusetts General Hospital Boston MA College of American Pathologists 2004. Materials are used with

More information

ANTICOAGULANT THERAPY ANTICOAGULANT THERAPY REVISITED 2005

ANTICOAGULANT THERAPY ANTICOAGULANT THERAPY REVISITED 2005 ANTICOAGULANT THERAPY REVISITED 2005 or, Which one(s) of these (#$%$#!@#^) drugs should be the one(s) I use, and for what? ANTICOAGULANT THERAPY One of most common treatments in hospital & out 2 nd most

More information

ANTICOAGULANT THERAPY REVISITED Thrombosis is a complication of underaggressive anticoagulant therapy ANTICOAGULANT THERAPY.

ANTICOAGULANT THERAPY REVISITED Thrombosis is a complication of underaggressive anticoagulant therapy ANTICOAGULANT THERAPY. ANTICOAGULANT THERAPY REVISITED 2005 or, Which one(s) of these (#$%$#!@#^) drugs should be the one(s) I use, and for what? ANTICOAGULANT THERAPY Goals of Therapy PREVENTION OF THROMBOEMBOLISM!!! Stop propagation

More information

TSOAC Case Study 1. Question. TSOAC Case Study 1 Continued

TSOAC Case Study 1. Question. TSOAC Case Study 1 Continued TSOAC Case Study 1 An otherwise healthy 56-year-old man presents to the emergency department with left leg pain and swelling for the last 3 days. Compression ultrasonography confirms left common femoral

More information

HEPARIN INDUCED THROMBOCYTOPENIA. Cortney Gandy PharmD candidate 2017 University of Kentucky

HEPARIN INDUCED THROMBOCYTOPENIA. Cortney Gandy PharmD candidate 2017 University of Kentucky 1 HEPARIN INDUCED THROMBOCYTOPENIA Cortney Gandy PharmD candidate 2017 University of Kentucky 2 Objectives Be able to explain the etiology of HIT Discuss the appropriate agents when treating HIT 3 Lets

More information

ISIS PHARMACEUTICALS. ISIS-FXI Rx Program Update. Webcast December 8, 2014

ISIS PHARMACEUTICALS. ISIS-FXI Rx Program Update. Webcast December 8, 2014 ISIS PHARMACEUTICALS ISIS-FXI Rx Program Update Webcast December 8, 2014 Introduction Stan Crooke, M.D., Ph.D. CEO and Chairman, Isis Pharmaceuticals 2 Forward Looking Language Statement This presentation

More information

The Role Of Point of Care Coagulation Testing (POCCT) in Patient Blood Management. Elham Khalaf Adeli

The Role Of Point of Care Coagulation Testing (POCCT) in Patient Blood Management. Elham Khalaf Adeli The Role Of Point of Care Coagulation Testing (POCCT) in Patient Blood Management Elham Khalaf Adeli Overview PBM, bleeding management, Coagulation POC Testing Review of laboratory conventional coagulation

More information

Case 1. Case 1. Case 2. Case 2. Review of Bleeding Disorders Case 1

Case 1. Case 1. Case 2. Case 2. Review of Bleeding Disorders Case 1 Review of Bleeding Disorders Case 1 Robert I. Handin, MD Professor of Medicine, Harvard Medical School Hematology Division Brigham & Women s Hospital 20 year college student is home on spring break and

More information

Primary hemostasis. Vascular endothelium Vasoconstriction : local tissue factor, nervous system

Primary hemostasis. Vascular endothelium Vasoconstriction : local tissue factor, nervous system Primary hemostasis Vascular endothelium Vasoconstriction : local tissue factor, nervous system Platelet Plug Platelet Adhesion Platelet Activation Platelet Aggregation Platelet Plug Formation Secondary

More information

Update on the Direct Oral Anticoagulants (DOACs)

Update on the Direct Oral Anticoagulants (DOACs) Update on the Direct Oral Anticoagulants (DOACs) J. Randle Adair DO, PhD Internal Medicine New Mexico Cancer Center & Co-Chair, Anticoagulation Subcommittee Presbyterian Healthcare Services (PHS) Attending,

More information

Index. Autoimmune thrombocytopenic purpura (AITP), 100, 102, 105, 108, 187 Automated platelet counters, , 108

Index. Autoimmune thrombocytopenic purpura (AITP), 100, 102, 105, 108, 187 Automated platelet counters, , 108 A Accuracy, 6, 7, 15, 46, 52, 53, 61, 75, 100, 143, 144, 149, 166, 176, 178 Acquired coagulation disorders, 111 115 Acquired platelet disorders, 99 108 ACT. See Activated clotting time (ACT) Activated

More information

Factor Concentrates. More is better? Alexander Duncan MD Emory Medical Labs

Factor Concentrates. More is better? Alexander Duncan MD Emory Medical Labs Factor Concentrates. More is better? Alexander Duncan MD Emory Medical Labs Call from OR! Scenario -1 Patients is bleeding out! Don t ask why, what rate what s been done! We need blood now! What kind of

More information

General News. Product Notes. Instrument Notice HELENA SALES FORCE TO: FROM: SUBJECT: HELENA POINT OF CARE ROUND-UP/US DOMESTIC DATE: 9/1/2009

General News. Product Notes. Instrument Notice HELENA SALES FORCE TO: FROM: SUBJECT: HELENA POINT OF CARE ROUND-UP/US DOMESTIC DATE: 9/1/2009 TO: FROM: SUBJECT: HELENA SALES FORCE DATE: 9/1/2009 General News HELENA POINT OF CARE ROUND-UP/US DOMESTIC We have concluded a very large meeting with the AACC in Chicago. The leads have been processed

More information

Antithrombosis Management for Pediatric VAD and Beyond

Antithrombosis Management for Pediatric VAD and Beyond Antithrombosis Management for Pediatric VAD and Beyond Christina VanderPluym M.D. Director of Ventricular Assist Device and Cardiac Antithrombosis Program Boston Children s Hospital, USA Disclosures I

More information

Coagulopathy Case-2. Andy Nguyen, M.D. 2009

Coagulopathy Case-2. Andy Nguyen, M.D. 2009 Coagulopathy Case-2 Andy Nguyen, M.D. 2009 CLINICAL HISTORY A 42 year-old man brought to the emergency room with severe burn. Patient was rescued by firemen in a serious fire. He had been found unconscious

More information

Using TEG in the ED, OR, and ICU. Don H. Van Boerum, MD, FACS

Using TEG in the ED, OR, and ICU. Don H. Van Boerum, MD, FACS Using TEG in the ED, OR, and ICU Don H. Van Boerum, MD, FACS Trauma Surgeon, Director of Surgical Critical Care, Co-Director of Shock Trauma ICU, Intermountain Medical Center, Intermountain Healthcare

More information

Common Inherited Bleeding Disorders

Common Inherited Bleeding Disorders CAA 2015 Annual Conference Common Inherited Bleeding Disorders Bob Miller, A October 8, 2015 VWF has two jobs Loosely bound to protect FVIII and tether to site of injury All other coagulation factors also

More information

Manejo de la transfusión de plaquetas. Ileana López-Plaza, MD

Manejo de la transfusión de plaquetas. Ileana López-Plaza, MD Manejo de la transfusión de plaquetas Ileana López-Plaza, MD Thrombocytopenia Common in ICU setting 25-38% with< 100,000/µL 2-3 % with < 10,000/µL Common etiologies Drug-induced: heparin, antibiotics,

More information

Personal Disclosure. The Coagulation Cascade. Learning Objectives. Unfractionated Heparin (UFH): Mechanism of Action. Heparin: Mechanism of Action

Personal Disclosure. The Coagulation Cascade. Learning Objectives. Unfractionated Heparin (UFH): Mechanism of Action. Heparin: Mechanism of Action Personal Disclosure Heparin/Low Molecular Weight Heparin and Fondaparinux Pharmacology and Pharmacotherapy Mary Jane E. Mattern PharmD Pharmacist William W. Backus Hospital There are no actual or potential

More information

Novel Anti-coagulant Agents. David G Hovord BA MB BChir FRCA Clinical Assistant Professor University of Michigan

Novel Anti-coagulant Agents. David G Hovord BA MB BChir FRCA Clinical Assistant Professor University of Michigan Novel Anti-coagulant Agents David G Hovord BA MB BChir FRCA Clinical Assistant Professor University of Michigan Objectives Provide an overview of the normal coagulation, including perioperative testing

More information

General News. Product Notes

General News. Product Notes TO: HELENA POC DISTRIBUTORS FROM: HELENA POINT OF CARE SUBJECT: ROUND-UP/INTERNATIONAL DATE: 8/31/2009 ATTN: ROUNDUP READERS CLINICAL TRIAL SITES NEEDED! As Helena POC continues development of Cascade

More information

These handouts are only meant as a guide while you follow the presentation on the screen. Sometimes the speaker will change some of the slides.

These handouts are only meant as a guide while you follow the presentation on the screen. Sometimes the speaker will change some of the slides. These handouts are only meant as a guide while you follow the presentation on the screen. Sometimes the speaker will change some of the slides. If you would like the 1 slide per page handouts, please ask

More information

Drugs used in Thromboembolic Disease. Munir Gharaibeh, MD, PhD, MHPE Department of Pharmacology Faculty of Medicine October 2014

Drugs used in Thromboembolic Disease. Munir Gharaibeh, MD, PhD, MHPE Department of Pharmacology Faculty of Medicine October 2014 Drugs used in Thromboembolic Disease Munir Gharaibeh, MD, PhD, MHPE Department of Pharmacology Faculty of Medicine October 2014 Drugs used in Thromboembolic Disease Anticoagulants: Heparin. Oral anticoagulants.

More information

Common Inherited Coagulation Disorders. Inherited Coagulation Disorders. All coagulation factors and platelets in circulation (unactivated)

Common Inherited Coagulation Disorders. Inherited Coagulation Disorders. All coagulation factors and platelets in circulation (unactivated) Common Inherited Coagulation Disorders Bob Miller, A 2017 Inherited Coagulation Disorders Brief review of coagulation Disorders related to platelet dysfunction (not the acquired thrombocytopenias) Disorders

More information

Vesalius SCALpel : Coagulation. Coagulation

Vesalius SCALpel : Coagulation. Coagulation Vesalius SCALpel : Coagulation Coagulation Clotting tests injury attracts platelets chemoattractants: platelet derived growth factor (PDGF), transforming growth factor beta (TGF beta) platelets release

More information

Physiology Unit 3 HEMATOLOGY

Physiology Unit 3 HEMATOLOGY Physiology Unit 3 HEMATOLOGY In Physiology Today Hematocrit Percentage of blood volume that is erythrocytes 45% in men 42% in women Average blood volume in is 5 L Plasma Large amounts of organic/inorganic

More information

argatroban, 100mg/ml, concentrate for solution for infusion (Exembol) SMC No. (812/12) Mitsubishi Pharma Europe Ltd

argatroban, 100mg/ml, concentrate for solution for infusion (Exembol) SMC No. (812/12) Mitsubishi Pharma Europe Ltd argatroban, 100mg/ml, concentrate for solution for infusion (Exembol) SMC No. (812/12) Mitsubishi Pharma Europe Ltd 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment

More information

Pharmacology Lecture 5. Anticoagulants

Pharmacology Lecture 5. Anticoagulants Pharmacology Lecture 5 Anticoagulants General overview Anti-thrombotic Drugs Antiplatlets Anticoagulants Fibrinolytics Anticoagulants Indirect Thrombin Inhibitors Anti-thrombotic effect is exerted by interaction

More information

Improving Outcomes of Cardiac Surgery with a Point-of-Care Based Transfusion Algorithm

Improving Outcomes of Cardiac Surgery with a Point-of-Care Based Transfusion Algorithm Improving Outcomes of Cardiac Surgery with a Point-of-Care Based Transfusion Algorithm Summer Syed (local PI) Keyvan Karkouti Deputy Anesthesiologist-in-Chief, Toronto General Hospital, University Health

More information

The Coagulation Workup In The Office Setting

The Coagulation Workup In The Office Setting CAA Conference alm Springs 2012 The Coagulation Workup In The Office Setting CAA Conference alm Springs, October 2012 Robert Miller, A-C Henoch-Schoenlein urpura 1 CAA Conference alm Springs 2012 2 CAA

More information

Anticoagulation in VTE The Haematologist s Perspective. Dr. M.D. Maina FRCP Edin.

Anticoagulation in VTE The Haematologist s Perspective. Dr. M.D. Maina FRCP Edin. Anticoagulation in VTE The Haematologist s Perspective Dr. M.D. Maina FRCP Edin. Disclosures None The coagulation process that leads to haemostasis involves a complex set of reactions involving approximately

More information

Adv Pathophysiology Unit 4 Page 1 of 10. Learning Objectives for this file:

Adv Pathophysiology Unit 4 Page 1 of 10. Learning Objectives for this file: Adv Pathophysiology Unit 4 Page 1 of 10 Learning Objectives for this file: Topics include structure & function of: 1. Coagulation process platelets, clotting factors 2. Coagulation cascade formation of

More information

Evaluation of Complex Coagulation Cases: Case-Based Illustrations of Important Issues

Evaluation of Complex Coagulation Cases: Case-Based Illustrations of Important Issues Evaluation of Complex Coagulation Cases: Case-Based Illustrations of Important Issues Kristi J. Smock, MD Associate Professor of Pathology University of Utah Health Sciences Center Medical Director, Hemostasis/Thrombosis

More information

Ch 13: Blood. What does blood do? Transport: Regulation: Protection:

Ch 13: Blood. What does blood do? Transport: Regulation: Protection: Ch 13: Blood What does blood do? Transport: Regulation: Protection: SLOs Describe the composition of plasma and list the major functions of plasma proteins. Map hematopoiesis, starting from a pluripotent

More information

Pharmacotherapy Management in Patients with Extracorporeal Membrane Oxygenation

Pharmacotherapy Management in Patients with Extracorporeal Membrane Oxygenation Pharmacotherapy Management in Patients with Extracorporeal Membrane Oxygenation Ayesha Ather, PharmD, BCPS College of Pharmacy, Adjunct Assistant Professor University of Kentucky Faculty Disclosure I have

More information

LABORATORY APPROCH TO THE BLEEDING PATIENT

LABORATORY APPROCH TO THE BLEEDING PATIENT Anne Winkler, MD Emory University School of Medicine, Atlanta Georgia Assistant Professor, Pathology & Laboratory Medicine Medical Director, Transfusion Service, Grady Health System Assistant Director,

More information

Plasma Testing in the Clinical Coagulation Laboratory: New drugs, new problems.

Plasma Testing in the Clinical Coagulation Laboratory: New drugs, new problems. Test Plasma Testing in the Clinical Coagulation Laboratory: New drugs, new problems. Karen A. Moffat BEd, MSc, ART, FCSMLS(D) Technical Specialist, Coagulation, HRLMP Assistant Professor, Department of

More information

Laboratory investigation in the Bleeding Patient. Dr Craig Taylor Consultant Haematologist May 2016

Laboratory investigation in the Bleeding Patient. Dr Craig Taylor Consultant Haematologist May 2016 Laboratory investigation in the Bleeding Patient Dr Craig Taylor Consultant Haematologist May 2016 Introduction Bleeding is common May consume significant resources Crossmatched blood Lab results may be

More information

Hemostasis. by Mohie-Aldien Elsayed

Hemostasis. by Mohie-Aldien Elsayed Hemostasis by Mohie-Aldien Elsayed Hemostasis Hemostasis is defined as the process that maintains the flowing blood in a fluid state and confined to the circulatory system Coagulation prevents excess blood

More information

Local vasoconstriction. is due to local spasm of the smooth muscle (symp. reflex) can be maintained by platelet vasoconstrictors

Local vasoconstriction. is due to local spasm of the smooth muscle (symp. reflex) can be maintained by platelet vasoconstrictors Hemostasis Hemostasis ( hemo =blood; sta= remain ) is the stoppage of bleeding, which is vitally important when blood vessels are damaged. Following an injury to blood vessels several actions may help

More information

Hypercoagulation. CP Conference 11/14/2006

Hypercoagulation. CP Conference 11/14/2006 Hypercoagulation CP Conference 11/14/2006 Overview Hypercoagulation: poorly understood phenomena No definite cause is identified in > 40% of cases Three major factors in thrombus formation (Rudolf Virchow,

More information

New factor concentrates on the way to the market

New factor concentrates on the way to the market New factor concentrates on the way to the market ISCB, Copenhagen, 1 September 2015 John R. Hess, MD, MPH, FACP, FAAAS Professor of Laboratory Medicine and Hematology Medical Director, Transfusion Service,

More information

Category Storage Shelf Life Additional Criteria

Category Storage Shelf Life Additional Criteria CE Update [blood banking/transfusion medicine] Blood Components for Hemostasis Jun Teruya, MD, DSc, and Glenn Ramsey, MD From the Department of Pathology, Northwestern University Medical School, Chicago.

More information

Laboratory Monitoring of Anticoagulation

Laboratory Monitoring of Anticoagulation Michael Smith, Pharm. D., BCPS, CACP East Region Pharmacy Clinical Manager Hartford HealthCare Learning Objectives Explain the role of common laboratory tests used in monitoring of anticoagulation therapy.

More information

Hemostasis and Thrombosis

Hemostasis and Thrombosis Hemostasis Hemostasis and Thrombosis Normal hemostasis is a consequence of tightly regulated processes that maintain blood in a fluid state in normal vessels, yet also permit the rapid formation of a hemostatic

More information

Basic coagulation applications and case studies

Basic coagulation applications and case studies Basic coagulation applications and case studies Jing Jin Clinical laboratory Scientist (MLS, ASCP) - Coagulation/Hematology Stanford University Hospital and Clinics 1 Agenda Overview about 3 major phases

More information

EDUCATIONAL COMMENTARY D-DIMER UPDATE

EDUCATIONAL COMMENTARY D-DIMER UPDATE EDUCATIONAL COMMENTARY D-DIMER UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits see the Continuing

More information

DOACs Can Be Reversed!

DOACs Can Be Reversed! 1 DOACs Can Be Reversed! AC Forum 14 th National Conference April 21, 2017 Adam Cuker, MD, MS Perelman School of Medicine University of Pennsylvania 2 Full disclosures (last 12 months) Research support

More information

Veins Valves prevent engorgement and backflow. Baroreceptor reflex. Veins returning blood

Veins Valves prevent engorgement and backflow. Baroreceptor reflex. Veins returning blood Veins have large radii and low resistance. Walls are thin, not elastic Most blood volume is in veins Veins returning blood Veins Valves prevent engorgement and backflow Sympathetic NS constricts veins

More information

Caplacizumab. Wholly-owned anti-vwf Nanobody

Caplacizumab. Wholly-owned anti-vwf Nanobody 1 Caplacizumab Wholly-owned anti-vwf Nanobody First-in-class bivalent Nanobody with Orphan Drug Status and patent protection up to 2035 Developed for the treatment of acquired thrombotic thrombocytopenic

More information

Coagulation Cascade. TF-VIIa. Tissue Factor + VII. XIIa. Prothrombin. XIa. IXa. VIIIa. Thrombin. XL- Fibrin. XIII Monomer. Fibrinogen.

Coagulation Cascade. TF-VIIa. Tissue Factor + VII. XIIa. Prothrombin. XIa. IXa. VIIIa. Thrombin. XL- Fibrin. XIII Monomer. Fibrinogen. Coagulation Cascade Intrinsic Pathway Extrinsic Pathway Contact Activation XIIa XI XIa Prekallikrein HMW Kininogen IX IXa Ca 2+ Anticoagulation proteins: Protein C, Protein S, Antithrombin III, TFPI TF

More information

Handouts. Handouts 1/28/2016. Understanding the Misunderstood Disease of Heparin Induced Thrombocytopenia (HIT) OKSANA VOLOD M.D.

Handouts. Handouts 1/28/2016. Understanding the Misunderstood Disease of Heparin Induced Thrombocytopenia (HIT) OKSANA VOLOD M.D. Understanding the Misunderstood Disease of Heparin Induced Thrombocytopenia (HIT) OKSANA VOLOD M.D., FCAP Director, Pathology and Laboratory Medicine Residency Program Cedars-Sinai Medical Center Los Angeles,

More information

New Anticoagulants Linda Liu, M.D.

New Anticoagulants Linda Liu, M.D. Difficult Task New Anticoagulants Professor UCSF Dept of Anesthesia 15 minutes! Emphasis on 2 new oral anticoagulants Dabigatran Rivaroxaban Relation to anesthesia Rapid reversal Regional anesthesia UC

More information

The Incidence of Recognized Heparin- Induced Thrombocytopenia in a Large, Tertiary Care Teaching Hospital*

The Incidence of Recognized Heparin- Induced Thrombocytopenia in a Large, Tertiary Care Teaching Hospital* CHEST The Incidence of Recognized Heparin- Induced Thrombocytopenia in a Large, Tertiary Care Teaching Hospital* Maureen A. Smythe, PharmD, FCCP; John M. Koerber, PharmD; and Joan C. Mattson, MD Original

More information

UW Medicine Alternative Monitoring for Antithrombotic Agents

UW Medicine Alternative Monitoring for Antithrombotic Agents Tags: monitoring alternative monitoring SUMMARY OF ANTICOAGULATION LAB TESTS AT UWMedicine Description Order Code Specimen Collection Availability Turn-Around Time Anti Xa Based Tests antixa for heparin

More information

Alberta Health Services - Edmonton Zone Massive Hemorrhage Protocol

Alberta Health Services - Edmonton Zone Massive Hemorrhage Protocol This document applies to all Covenant and AHS sites. Client Resource 23: Alberta Health Services - Edmonton Zone Regional Laboratory Services This document is applicable at site(s): GNH MIS RAH SGH UAH

More information

BLOOD COAGULATION. 1. The initial phase of the process is vascular constriction. This limits the flow of blood to the area of injury.

BLOOD COAGULATION. 1. The initial phase of the process is vascular constriction. This limits the flow of blood to the area of injury. BLOOD COAGULATION The ability of the body to control the flow of blood following vascular injury is paramount to continued survival. The process of blood clotting and then the subsequent dissolution of

More information

Generate Knowledge. STic Expert HIT: for a rapid and confident exclusion of Heparin Induced Thrombocytopenia. Jamal Barsheed

Generate Knowledge. STic Expert HIT: for a rapid and confident exclusion of Heparin Induced Thrombocytopenia. Jamal Barsheed Generate Knowledge STic Expert HIT: for a rapid and confident exclusion of Heparin Induced Thrombocytopenia Jamal Barsheed Outline What is HIT? description diagnosis treatment clinicians and labs needs

More information

Analysis of the Anticoagulant Market

Analysis of the Anticoagulant Market MEDICAL DEVICES PHARMACEUTICALS CHEMICALS FOOD & BEVERAGE ELECTRONICS Analysis of the Anticoagulant Market VPG Publications, Consulting, Clients www.vpgcorp.com VPG Market Research Reports www.vpgmarketresearch.com

More information

Disclosure (s) Relevant financial relationship(s) None Off-label usage None Change in slide set You betcha! (YES!) 2015 MFMER slide-1

Disclosure (s) Relevant financial relationship(s) None Off-label usage None Change in slide set You betcha! (YES!) 2015 MFMER slide-1 Disclosure (s) Relevant financial relationship(s) None Off-label usage None Change in slide set You betcha! (YES!) 2015 MFMER slide-1 Learning Objectives Explain the concept of thrombophilia Recognize

More information

LABORATORY DIAGNOSIS OF BLEEDING DISORDERS

LABORATORY DIAGNOSIS OF BLEEDING DISORDERS LABORATORY DIAGNOSIS OF BLEEDING DISORDERS Primary & Secondary Hemostasis Disorders http://.columbia.edu/itc/hs/medical/selective/advclinicalpathology/2004/lecture/lab%20diagnosis%20of%20bleeding%20disorders.ppt

More information

UvA-DARE (Digital Academic Repository) Factor XI as target for antithrombotic therapy van Montfoort, M.L. Link to publication

UvA-DARE (Digital Academic Repository) Factor XI as target for antithrombotic therapy van Montfoort, M.L. Link to publication UvA-DARE (Digital Academic Repository) Factor XI as target for antithrombotic therapy van Montfoort, M.L. Link to publication Citation for published version (APA): van Montfoort, M. L. (2014). Factor XI

More information

Blood 101. Dr. Karen L. Dallas. Medical Director, Hematopathology & Transfusion Medicine Providence Health Care

Blood 101. Dr. Karen L. Dallas. Medical Director, Hematopathology & Transfusion Medicine Providence Health Care Blood 101 Dr. Karen L. Dallas Medical Director, Hematopathology & Transfusion Medicine Providence Health Care Alternate Title?: Inside Knowledge About How We re Helping You in the Hematology Laboratory

More information

PROPHYLAXIS IN THE ORTHOPEDIC PATIENT: Martin H. Ellis MD Hematology Institute and Blood Bank Meir Medical Center Kfar Saba

PROPHYLAXIS IN THE ORTHOPEDIC PATIENT: Martin H. Ellis MD Hematology Institute and Blood Bank Meir Medical Center Kfar Saba VENOUS THROMBOEMBOLISM PROPHYLAXIS IN THE ORTHOPEDIC PATIENT: Martin H. Ellis MD Hematology Institute and Blood Bank Meir Medical Center Kfar Saba OVERVIEW Biochemistry of coagulation Pathogenesis of VTE

More information

Sign up to receive ATOTW weekly -

Sign up to receive ATOTW weekly - BLOOD PHYSIOLOGY PART 2 ANAESTHESIA TUTORIAL OF THE WEEK 231 11 TH JULY 2011 Dr Karen Hayes Royal Devon & Exeter Correspondence to: kmhayes@hotmail.co.uk QUESTIONS Before continuing, try to answer the

More information

Understanding the Hazards of Heparin

Understanding the Hazards of Heparin Understanding the Hazards of Heparin 1 Contact Hours First Published: March 31, 2012 Course Revised: May, 2018 Course Expires: May 31, 2021 Reproduction and distribution of these materials is prohibited

More information

CE Update. Heparins: Clinical Use and Laboratory Monitoring

CE Update. Heparins: Clinical Use and Laboratory Monitoring Heparins: Clinical Use and Laboratory Monitoring Maureane Hoffman, MD, PhD (Chief, Transfusion Service and Hematology Laboratories, Pathology & Laboratory Medicine Service, Durham VA Medical Center, Durham,

More information

DOACs: When and how to measure their anticoagulant effect

DOACs: When and how to measure their anticoagulant effect DOACs: When and how to measure their anticoagulant effect Stavroula Tsiara MD, PhD, FRCP Associate Professor of Internal Medicine University of Ioannina, Greece NOACs NOACs, TSOACs, DOACs (ISTH) Target

More information

Venous thromboembolism (VTE) Can Biomarkers Help to Guide Duration of Therapy After VTE? New Chest Guidelines 2016

Venous thromboembolism (VTE) Can Biomarkers Help to Guide Duration of Therapy After VTE? New Chest Guidelines 2016 Venous thromboembolism (VTE) Can Biomarkers Help to Guide Duration of Therapy After VTE? Marlene Grenon, MD Associate Professor of Surgery University of California San Francisco UCSF Vascular Surgery Symposium

More information

Special Coagulation - APC Resistance. DiaPharma Group, Inc. Customer Service: Technical Support:

Special Coagulation - APC Resistance. DiaPharma Group, Inc. Customer Service: Technical Support: Special Coagulation - APC Resistance DiaPharma Group, Inc. Customer Service: 1.800.526.5224 Technical Support:1.800.447.3846 www.diapharma.com 1 Review of Hemostasis Overview Pathways of coagulation, anticoagulation,

More information

Haemostasis. The function of haemostasis is: to prevent blood loss from injured vessels. to stop bleeding. to prevent thrombosis

Haemostasis. The function of haemostasis is: to prevent blood loss from injured vessels. to stop bleeding. to prevent thrombosis Haemostasis Haemostasis The function of haemostasis is: to prevent blood loss from injured vessels to stop bleeding to prevent thrombosis Haemostasis blood endothelium basement membrane subendothelium

More information

D-Stat Dry Topical Hemostat Proven to Reduce Time-to-Hemostasis 1,2

D-Stat Dry Topical Hemostat Proven to Reduce Time-to-Hemostasis 1,2 D-Stat Dry Topical Hemostat Proven to Reduce Time-to-Hemostasis 1,2 Clinical Data to Support a True Hemostat Results are from a 376-patient, five-center, prospective randomized U.S. clinical study evaluating

More information

Laboratory Monitoring of Heparin Therapy: Partial Thromboplastin Time or Anti-Xa Assay?

Laboratory Monitoring of Heparin Therapy: Partial Thromboplastin Time or Anti-Xa Assay? Laboratory Monitoring of Heparin Therapy: Partial Thromboplastin Time or Anti-Xa Assay? Christopher M. Lehman, MD, Elizabeth L. Frank, PhD (University of Utah Pathology Department and ARUP Institute for

More information

Disclosures. Thromboelastography. TEG Methodology. TEG Output. Thromboelastography (TEG): Basics & Clinical Applications

Disclosures. Thromboelastography. TEG Methodology. TEG Output. Thromboelastography (TEG): Basics & Clinical Applications Thromboelastography (TEG): Basics & Clinical Applications Paula J. Santrach MD Associate Professor, Laboratory Medicine Mayo Clinic Rochester, MN Disclosures Relevant financial relationships NONE Off label

More information

3 : 34. Pankaj Manoria, P C Manoria, Bhopal

3 : 34. Pankaj Manoria, P C Manoria, Bhopal 3 : 34 Newer Antithrombins and anticoagulants Introduction Thrombosis is a leading cause of morbidity and mortality but for decades, anticoagulant therapy has usually consisted of unfractionate heparin

More information

An Unusual Presentation in a Man of Advanced Age. Robert E. Richard

An Unusual Presentation in a Man of Advanced Age. Robert E. Richard An Unusual Presentation in a Man of Advanced Age Robert E. Richard An Unusual Presentation by a Man of Advanced Age Robert E. Richard A few observations on what ht makes aesaa good fellows eo sconference

More information

Veins Valves prevent engorgement and backflow. Baroreceptor reflex. Veins returning blood

Veins Valves prevent engorgement and backflow. Baroreceptor reflex. Veins returning blood Veins have large radii and low resistance. Walls are thin, not elastic Most blood volume is in veins Veins returning blood Veins Valves prevent engorgement and backflow Sympathetic NS constricts veins

More information

Disclosures. I have received research funding from: I have received consulting fees/honoraria from: Novo Nordisk CSL-Behring Boehringer Ingelheim

Disclosures. I have received research funding from: I have received consulting fees/honoraria from: Novo Nordisk CSL-Behring Boehringer Ingelheim Test Disclosures I have received research funding from: Novo Nordisk CSL-Behring Boehringer Ingelheim I have received consulting fees/honoraria from: Novo Nordisk CSL-Behring Baxter The Medicines Company

More information